Manufacturing

Articles

Samsung BioLogics begins construction on their third facility in Songdo, Korea.

Samsung BioLogics Breaks Ground on Third Facility

Seqirus, CSL Limited’s influenza vaccine business, announced the opening of their corporate headquarters in the United Kingdom.

Seqirus Opens Corporate Headquarters in the United Kingdom

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

FDA confirmed quality focus while Congress moved to bolster biomedical innovation.

New Drugs and New Initiatives Shaped 2015

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Biotech boom, niche markets, smaller batch sizes and high potency manufacturing are among the key trends shaping the pharmaceutical industry of the 21st century, according to Christian Treitel from Bosch Packaging Technology.

Pharma Trends—From Biologics for Niche Patient Populations to Isolators and Containment for HPAPI Manufacturing

South Africa’s Biovac Institute, which develops and produces vaccines for the country, launched a public-private partnership with Pfizer to enable local manufacturing of Prevenar 13, a vaccine against pneumonia-causing bacteria.

Pfizer Transfers Vaccine Technology for Production in South Africa

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

While biologics development grabs investor interest, small-molecule APIs still hold two-thirds of the drug-development pipeline.

CMOs Ride Continuing Strength of Small-Molecule Drug Sector

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

According to a third-quarter earnings report, Pfizer’s vaccine business contributed nearly 14% to its total revenue.

Revenues from Pfizer’s Vaccine Business Increase

Univercells will integrate its single-use bioprocess with the Takeda vaccines production platform to allow local production.

Univercells Partners with Takeda to Develop Vaccine Manufacturing

The PDA report discusses qualification and operational handling of passive thermal protection systems.

PDA Releases Report on Passive Thermal Protection Systems

Andrew Harrison is chief regulatory affairs officer and general counsel with Regulatory Compliance Associates.

Susan J. Schniepp is a fellow at Regulatory Compliance Associates, Inc. and a member of Pharmaceutical Technology's Editorial Advisory Board.

Susan Schniepp, distinguished fellow, and Andrew Harrison, chief regulatory affairs officer and general counsel, both of Regulatory Compliance Associates, discuss performing investigations of biological products.

Manufacturing, Biologic Drugs